Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Cyrus Badshah"'
Autor:
Vu Dinh Thiem, Nguyen Dang Quang, Nguyen Hai Tuan, Kyeongmi Cheon, Nancy Gallagher, Alain Luxembourg, Thomas Group, Cyrus Badshah
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 7, Pp 1980-1985 (2021)
This open-label, single-center, Phase 3 study (NCT03546842) assessed the immunogenicity and safety of the nine-valent human papillomavirus (9vHPV; HPV6/11/16/18/31/33/45/52/58) vaccine in Vietnamese males and females, with the aim to support 9vHPV va
Externí odkaz:
https://doaj.org/article/21f29e53122346d1a140f3d78bb5fe18
Autor:
Susanne K. Kjaer, Mari Nygård, Karin Sundström, Joakim Dillner, Laufey Tryggvadottir, Christian Munk, Sophie Berger, Espen Enerly, Maria Hortlund, Ágúst Ingi Ágústsson, Kaj Bjelkenkrantz, Katrin Fridrich, Ingibjorg Guðmundsdóttir, Sveinung Wergeland Sørbye, Oliver Bautista, Thomas Group, Alain Luxembourg, J. Brooke Marshall, David Radley, Yi Shen Yang, Cyrus Badshah, Alfred Saah
Publikováno v:
EClinicalMedicine, Vol 23, Iss , Pp 100401- (2020)
Background: The quadrivalent human papillomavirus (qHPV) vaccine prevented vaccine HPV type-related infection and disease in young women in the 4-year FUTURE II efficacy study (NCT00092534). We report long-term effectiveness and immunogenicity at the
Externí odkaz:
https://doaj.org/article/ef777c48074b460cade266cc0f37f1b9
Autor:
Randi Y. Leavitt, Anders Viberg, Carolyn R. Cho, Craig Fancourt, Julie A. Stone, Sreeraj Macha, Yoshihiko Murata, Marita Prohn, Cyrus Badshah, Philip Sabato, Kevin Dykstra, Casey Davis
Publikováno v:
Clinical Pharmacology & Therapeutics. 111:485-495
The cytomegalovirus (CMV) viral terminase inhibitor letermovir is approved for prophylaxis of CMV infection and disease in adult CMV-seropositive allogeneic hematopoietic stem cell transplantation recipients. In a phase III trial (NCT02137772), leter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fe4008fba73a1a300982aed78a27fdc
https://doi.org/10.1002/cpt.2456
https://doi.org/10.1002/cpt.2456
Autor:
Shahrul Mt-Isa, Hong Wan, Yoav Golan, Cyrus Badshah, Sanjeet Dadwal, Valerie L Teal, Yuexin Tang
Publikováno v:
PharmacoEconomics Open
Background Allogeneic hematopoietic stem cell transplantation (HSCT) is associated with substantial healthcare resource use, particularly when recipients develop cytomegalovirus (CMV) infection. Letermovir reduced post-HSCT CMV infection risk compare
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41c844356fcc2f5b0cdf9b0d54a3454a
https://doi.org/10.1007/s41669-021-00264-9
https://doi.org/10.1007/s41669-021-00264-9
Autor:
Roy F. Chemaly, Wendy W. Yeh, Per Ljungman, Valerie L Teal, Randi Y. Leavitt, Cyrus Badshah, Hong Wan, Francisco M. Marty, Joan R. Butterton
Publikováno v:
American Journal of Transplantation. 20:1703-1711
Letermovir, a cytomegalovirus (CMV) terminase-complex inhibitor, is indicated for prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of allogeneic hematopoietic cell transplantation (HCT). In a phase III, double-blind, rand
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cca12ae51a30f4471fd51f6b2f969ea7
https://doi.org/10.1111/ajt.15764
https://doi.org/10.1111/ajt.15764
Autor:
Sanjeet Singh Dadwal, Domenico Russo, Matthias Stelljes, Michael Schmitt, Sylvain Pilorge, Valerie L. Teal, Barbara A. Haber, Charlene Bopp, Cyrus Badshah
Publikováno v:
Transplantation and Cellular Therapy. 29:S64
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f55c36b71a36437b48ce493724b0442a
https://doi.org/10.1016/s2666-6367(23)00145-8
https://doi.org/10.1016/s2666-6367(23)00145-8
Autor:
Cyrus Badshah, Kathleen M. Mullane, Andrew J. Ullmann, Shariq Haider, Randi Y. Leavitt, Yoshihiko Murata, Francisco M. Marty, Johan Maertens, Per Ljungman, Hong Wan, Michael Boeckh, Emily A. Blumberg, Sanjeet Dadwal, Yuta Katayama, Roy F. Chemaly, Nicholas A. Kartsonis, David R. Snydman, Hermann Einsele, Yoshinobu Kanda, Mark J. DiNubile, Rafael F. Duarte, Janice M. Brown, Valerie L Teal
Publikováno v:
New England Journal of Medicine. 377:2433-2444
BACKGROUND: Cytomegalovirus (CMV) infection remains a common complication after allogeneic hematopoietic-cell transplantation. Letermovir is an antiviral drug that inhibits the CMV-terminase complex. METHODS: In this phase 3, double-blind trial, we r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e6160b718072a6e17d3f9a0a037de8f
https://doi.org/10.1056/nejmoa1706640
https://doi.org/10.1056/nejmoa1706640
Autor:
Alexander Wong, Deborah Goldstein, Anthony Rodgers, Sushma Kumar, Peter Sklar, Valerie L Teal, Cyrus Badshah, Hedy Teppler, George J. Hanna, Anton Pozniak, Josep Mallolas, Deborah A. Hepler, Edwin DeJesus, Carey Hwang, Jean-Michel Molina, Margaret A. Johnson
Publikováno v:
Journal of Acquired Immune Deficiency Syndromes (1999)
Supplemental Digital Content is Available in the Text.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34ed3df7dfa113c9003c233585bf3771
https://pubmed.ncbi.nlm.nih.gov/31425317
https://pubmed.ncbi.nlm.nih.gov/31425317
Autor:
Cyrus Badshah, Nicholas A. Kartsonis, Hong Wan, Michael Schmitt, Johan Maertens, Francisco M. Marty, Randi Y. Leavitt, Joan R. Butterton, Valerie L Teal, Roy F. Chemaly, Per Ljungman, Yoshihiko Murata, Kendra Sarratt
Publikováno v:
Clin Infect Dis
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Background In a phase 3 trial, letermovir reduced clinically significant cytomegalovirus infections (CS-CMVi) and all-cause mortality at week 24 versus placebo in CMV-seropositive allogeneic hematopoietic cell transplantation (HCT) recipients. This p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d7fd57836fc978f0f5ae986c1e7fadb
https://pubmed.ncbi.nlm.nih.gov/31179483
https://pubmed.ncbi.nlm.nih.gov/31179483
Autor:
Roy F. Chemaly, Francisco M. Marty, Valerie L Teal, Cyrus Badshah, Wendy W. Yeh, Per Ljungman, Randi Y. Leavitt, Hong Wan, Joan R. Butterton
Publikováno v:
Open Forum Infectious Diseases
Background LET prophylaxis through HCT Week 14 was highly effective in preventing clinically significant CMV infection (CS-CMVi), had a good safety profile, and was associated with lower all-cause mortality by HCT Week 24 compared with placebo (PBO).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e76b8838849fabde836a51143466c07
http://europepmc.org/articles/PMC6252851
http://europepmc.org/articles/PMC6252851